Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
Titel:
Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) Group
Auteur:
Lorusso, D. Ferrandina, G. Pignata, S. Ludovisi, M. ViganĂ², R. Scalone, S. Scollo, P. Breda, E. Pietragalla, A. Scambia, G.